C3 and COVID-19: We suspect C3a may contribute to TMA-mediated renal injury (frequently seen in COVID-19-related AKI) (26), by inducing inflammation, activating the endothelium (27), and triggering platelet aggregation by binding of the C3a receptor (C3aR) on platelets (4, 28).